肝硬化或肝癌伴银屑病患者肝移植术后治疗经验

摘要

Objective To summarize the clinical experience of immunosuppressive therapy for recipients suffering from psoriasis after liver transplantation. Methods Five patients diagnosed with cirrhosis or hepatocellular carcinoma (HCC)complicated with psoriasis after liver transplantation were recruited in this clinical trial. All participants were positive for serum biomarkers of hepatitis B virus (HBV). Induction therapy was adopted before surgery. Immunosuppressive regime of tacrolimus (FK506),mycophenolate mofetil (MMF)and adrenal cortical hormone (hormone) was implemented early after surgery. The hormone use was terminated within 1 week. Three cases of cirrhosis complicated with HCC due to chronic HBV infection were gradually switched to sirolimus substitution treatment within 1 month after liver transplantation. Two patients with cirrhosis were administered with FK506 with or without MMF following liver transplantation. All patients received anti-HBV therapy. Baseline data,changes in psoriasis area and severity index (PASI)score and adjustment of postoperative immunosuppressive agents were analyzed. Results Five patients undergoing transplantation were followed up until the submission date with a mean duration of (8. 3 ±1 . 5 )years and survived. Compared with preoperative values,PASI score was significantly reduced at postoperative 6 months (P<0. 05 ). Two patients with cirrhosis had recurrent psoriasis at 2 years after liver transplantation. PASI score was significantly increased and steadily declined after sirolimus substitution therapy. These patients remained physically stable and did not progress at postoperative 3 years. Three patients suffering from cirrhosis complicated with HCC presented with no recurrence of psoriasis postoperatively. Conclusions Sirolimus-based immunosuppressive therapy can effectively control the progression of psoriasis in liver transplantation recipients. Anti-HBV treatment should be simultaneously implemented for HBV positive patients.%目的：总结患有银屑病的肝移植受者免疫抑制治疗的临床经验。方法以5例肝硬化或肝细胞癌（肝癌）伴银屑病的肝移植受者为研究对象，其乙型肝炎病毒（HBV）血清标志物均阳性。术前采用诱导方案，术后早期采用他克莫司（FK506）＋吗替麦考酚酯（MMF）＋肾上腺皮质激素（激素）三联免疫抑制方案，1周内停用激素。3例乙型病毒性肝炎（乙肝）后肝硬化合并肝癌肝移植患者1个月内逐步转换为西罗莫司替代治疗；2例乙肝后肝硬化肝移植受者患者一直采用FK506加或不加MMF方案。全部患者均予抗HBV治疗。分析其基本情况、银屑病皮损面积和严重性指数（PASI）评分变化及术后免疫抑制剂治疗方案的调整情况。结果5例患者肝移植术后至投稿日随访（8.3±1.5）年，均存活。与术前相比，患者术后6个月PASI评分明显降低（P＜0.05）。2例乙肝后肝硬化肝移植受者患者在术后2年后出现银屑病复发，PASI评分显著升高，改为西罗莫司替代FK506的治疗方案后逐步下降，术后3年开始维持在稳定状态，无进展；3例乙肝后肝硬化合并肝癌肝移植受者无复发。结论以西罗莫司为主的免疫抑制治疗方案可有效控制肝移植受者的银屑病病情，对HBV阳性患者应同时进行抗HBV治疗。